PRTA Fundamental Analysis - PROTHENA CORP PLC

Name: PROTHENA CORP PLC (PRTA) Stock
Brand: PROTHENA CORP PLC
Rating: 5.5 (3 reviews)

Fundamental Rating

Overall PRTA gets a fundamental rating of 3 out of 10. We evaluated PRTA against 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PRTA as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, PRTA is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PRTA has reported negative net income.

PRTA had a negative operating cash flow in the past year.

In the past 5 years PRTA reported 4 times negative net income.

PRTA had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of PRTA (-75.91%) is worse than 66.10% of its industry peers.

Looking at the Return On Equity, with a value of -93.40%, PRTA is in line with its industry, outperforming 47.65% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-75.91%
ROE	-93.4%
ROIC	N/A

ROA(3y)-19.63%

ROA(5y)-16.25%

ROE(3y)-23.37%

ROE(5y)-23.22%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRTA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PRTA does not have a ROIC to compare to the WACC, probably because it is not profitable.

PRTA has more shares outstanding than it did 1 year ago.

PRTA has more shares outstanding than it did 5 years ago.

PRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -1.20, we must say that PRTA is in the distress zone and has some risk of bankruptcy.

PRTA has a Altman-Z score (-1.20) which is comparable to the rest of the industry.

PRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-1.2

ROIC/WACCN/A

WACC7.59%

2.3 Liquidity

PRTA has a Current Ratio of 5.68. This indicates that PRTA is financially healthy and has no problem in meeting its short term obligations.

PRTA's Current ratio of 5.68 is fine compared to the rest of the industry. PRTA outperforms 61.21% of its industry peers.

A Quick Ratio of 5.68 indicates that PRTA has no problem at all paying its short term obligations.

PRTA has a Quick ratio of 5.68. This is in the better half of the industry: PRTA outperforms 61.77% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.68
Quick Ratio	5.68

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for PRTA have decreased strongly by -85.89% in the last year.

Looking at the last year, PRTA shows a very strong growth in Revenue. The Revenue has grown by 47.92%.

PRTA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 178.96% yearly.

EPS 1Y (TTM)-85.89%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%38.18%

Revenue 1Y (TTM)47.92%

Revenue growth 3Y-12.33%

Revenue growth 5Y178.96%

Sales Q2Q%148.97%

3.2 Future

The Earnings Per Share is expected to grow by 3.62% on average over the next years.

PRTA is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -11.01% yearly.

EPS Next Y-105.08%

EPS Next 2Y42.95%

EPS Next 3Y20.14%

EPS Next 5Y3.62%

Revenue Next Year-85.33%

Revenue Next 2Y6.43%

Revenue Next 3Y-32.75%

Revenue Next 5Y-11.01%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PRTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

With a Price/Forward Earnings ratio of 99.01, PRTA can be considered very expensive at the moment.

87.57% of the companies in the same industry are more expensive than PRTA, based on the Price/Forward Earnings ratio.

The average S&P500 Price/Forward Earnings ratio is at 34.59. PRTA is valued rather expensively when compared to this.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	99.01

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PRTA's earnings are expected to grow with 20.14% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y42.95%

EPS Next 3Y20.14%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PRTA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROTHENA CORP PLC

NASDAQ:PRTA (11/14/2025, 8:17:57 PM)

After market: 9.93 0 (0%)

9.93

-0.25 (-2.46%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-06 2025-11-06/amc

Earnings (Next)02-18 2026-02-18/amc

Inst Owners79.74%

Inst Owner Change-2.08%

Ins Owners19.24%

Ins Owner Change45.8%

Market Cap534.53M

Revenue(TTM)135.16M

Net Income(TTM)-302.92M

Analysts75.38

Price Target16.83 (69.49%)

Short Float %8.87%

Short Ratio4.81

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-20.83%

Min EPS beat(2)-28.86%

Max EPS beat(2)-12.81%

EPS beat(4)1

Avg EPS beat(4)-8.72%

Min EPS beat(4)-28.86%

Max EPS beat(4)8.41%

EPS beat(8)3

Avg EPS beat(8)47.94%

EPS beat(12)5

Avg EPS beat(12)36.25%

EPS beat(16)5

Avg EPS beat(16)20.6%

Revenue beat(2)0

Avg Revenue beat(2)-37.48%

Min Revenue beat(2)-55.76%

Max Revenue beat(2)-19.2%

Revenue beat(4)0

Avg Revenue beat(4)-42.43%

Min Revenue beat(4)-72.37%

Max Revenue beat(4)-19.2%

Revenue beat(8)2

Avg Revenue beat(8)106.61%

Revenue beat(12)3

Avg Revenue beat(12)61.95%

Revenue beat(16)3

Avg Revenue beat(16)29.55%

PT rev (1m)37.5%

PT rev (3m)-28.7%

EPS NQ rev (1m)0%

EPS NQ rev (3m)23.76%

EPS NY rev (1m)0%

EPS NY rev (3m)-17.24%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)23.78%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-35.37%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	99.01
P/S	51.69
P/FCF	N/A
P/OCF	N/A
P/B	1.65
P/tB	1.65
EV/EBITDA	N/A

EPS(TTM)-4.61

EYN/A

EPS(NY)0.1

Fwd EY1.01%

FCF(TTM)-3.58

FCFYN/A

OCF(TTM)-3.58

OCFYN/A

SpS0.19

BVpS6.03

TBVpS6.03

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-75.91%
ROE	-93.4%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-19.63%

ROA(5y)-16.25%

ROE(3y)-23.37%

ROE(5y)-23.22%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	20.11%
Cap/Sales	1.74%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.68
Quick Ratio	5.68
Altman-Z	-1.2

F-Score2

WACC7.59%

ROIC/WACCN/A

Cap/Depr(3y)132.78%

Cap/Depr(5y)92.67%

Cap/Sales(3y)1.38%

Cap/Sales(5y)5.33%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-85.89%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%38.18%

EPS Next Y-105.08%

EPS Next 2Y42.95%

EPS Next 3Y20.14%

EPS Next 5Y3.62%

Revenue 1Y (TTM)47.92%

Revenue growth 3Y-12.33%

Revenue growth 5Y178.96%

Sales Q2Q%148.97%

Revenue Next Year-85.33%

Revenue Next 2Y6.43%

Revenue Next 3Y-32.75%

Revenue Next 5Y-11.01%

EBIT growth 1Y-172.53%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year100%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-48.8%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-49.93%

OCF growth 3YN/A

OCF growth 5YN/A

PROTHENA CORP PLC / PRTA FAQ

What is the ChartMill fundamental rating of PROTHENA CORP PLC (PRTA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PRTA.

Can you provide the valuation status for PROTHENA CORP PLC?

ChartMill assigns a valuation rating of 1 / 10 to PROTHENA CORP PLC (PRTA). This can be considered as Overvalued.

What is the profitability of PRTA stock?

PROTHENA CORP PLC (PRTA) has a profitability rating of 0 / 10.

What is the financial health of PROTHENA CORP PLC (PRTA) stock?

The financial health rating of PROTHENA CORP PLC (PRTA) is 7 / 10.

PROTHENA CORP PLC (PRTA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

PROTHENA CORP PLC / PRTA FAQ

What is the ChartMill fundamental rating of PROTHENA CORP PLC (PRTA) stock?

Can you provide the valuation status for PROTHENA CORP PLC?

What is the profitability of PRTA stock?

What is the financial health of PROTHENA CORP PLC (PRTA) stock?